{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:42:12Z","timestamp":1785206532800,"version":"3.55.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2015,1,24]],"date-time":"2015-01-24T00:00:00Z","timestamp":1422057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0116135","type":"journal-article","created":{"date-parts":[[2015,1,24]],"date-time":"2015-01-24T19:17:15Z","timestamp":1422127035000},"page":"e0116135","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts"],"prefix":"10.1371","volume":"10","author":[{"given":"Maiko","family":"Matsushita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukiko","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Shiheido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,1,24]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajh.23390","article-title":"Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management","volume":"88","author":"SV Rajkumar","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma 2011","volume":"154","author":"JM Bird","year":"2011","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/OTT.S34498","article-title":"Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma","volume":"6","author":"E Terpos","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2040620713480155","article-title":"Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist","volume":"4","author":"AR McCurdy","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"Suppl 1","key":"ref5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2012.05.005","article-title":"Relapsed\/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance","volume":"49","author":"DS Siegel","year":"2012","journal-title":"Semin Hematol"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11899-011-0077-y","article-title":"New immunomodulatory drugs in myeloma","volume":"6","author":"MQ Lacy","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pharmthera.2012.07.004","article-title":"The application and biology of immunomodulatory drugs (IMiDs) in cancer","volume":"136","author":"B Pan","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"PL Bergsagel","year":"2013","journal-title":"Blood"},{"issue":"16","key":"ref9","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2011.36.5726","article-title":"Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival","volume":"30","author":"H Avet-Loiseau","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","article-title":"The prognostic significance of cytogenetics and molecular profiling in multiple myeloma","volume":"204","author":"JR Sawyer","year":"2011","journal-title":"Cancer Genet"},{"issue":"17","key":"ref11","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","article-title":"Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance","volume":"118","author":"MV Mateos","year":"2011","journal-title":"Blood"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","article-title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"51","author":"H Chang","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"e38878","DOI":"10.1371\/journal.pone.0038878","article-title":"A phthalimide derivative that inhibits centrosomal clustering is effective on multiple myeloma","volume":"7","author":"H Shiheido","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12185-013-1291-2","article-title":"Molecular pathogenesis of multiple myeloma: basic and clinical updates","volume":"97","author":"M Chesi","year":"2013","journal-title":"Int J Hematol"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/leu.2011.282","article-title":"Bisphosphonates as antimyeloma drugs","volume":"26","author":"ND Modi","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"N Raje","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF02623725","article-title":"Establishment of five human myeloma cell lines","volume":"25","author":"M Namba","year":"1989","journal-title":"In Vitro Cell Dev Biol"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood-2006-02-003103","article-title":"NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor","volume":"109","author":"W Du","year":"2007","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1038\/bcj.2013.13","article-title":"A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor","volume":"3","author":"Y Hattori","year":"2013","journal-title":"Blood Cancer J"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1083\/jcb.201111116","article-title":"Tks5-dependent formation of circumferential podosomes\/invadopodia mediates cell-cell fusion","volume":"197","author":"T Oikawa","year":"2012","journal-title":"J Cell Biol"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ctrv.2011.12.007","article-title":"Impact of bortezomib on bone health in myeloma: a review of current evidence","volume":"38","author":"M Zangari","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"25","key":"ref22","doi-asserted-by":"crossref","first-page":"26475","DOI":"10.1074\/jbc.M313973200","article-title":"Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos","volume":"279","author":"K Matsuo","year":"2004","journal-title":"J Biol Chem"},{"key":"ref23","first-page":"195","article-title":"NPM1\/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling","author":"MS Lindstrom","year":"2011"},{"issue":"23","key":"ref24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1038\/onc.2010.646","article-title":"Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases","volume":"30","author":"E Colombo","year":"2011","journal-title":"Oncogene"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrc1885","article-title":"Nucleophosmin and cancer","volume":"6","author":"S Grisendi","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"ref26","doi-asserted-by":"crossref","first-page":"16536","DOI":"10.1074\/jbc.M601386200","article-title":"Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem\/progenitor cells","volume":"281","author":"J Li","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.23404","article-title":"Acute myeloid leukemia: 2013 update on risk-stratification and management","volume":"88","author":"EH Estey","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.blre.2011.06.001","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy","volume":"25","author":"B Falini","year":"2011","journal-title":"Blood Rev"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/leu.2009.124","article-title":"Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications","volume":"23","author":"B Falini","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/gcc.20745","article-title":"NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm","volume":"49","author":"N Weinhold","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/prot.21504","article-title":"Crystal structure of human nucleophosmin-core reveals plasticity of the pentamer-pentamer interface","volume":"69","author":"HH Lee","year":"2007","journal-title":"Proteins"},{"issue":"30","key":"ref32","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/onc.2008.54","article-title":"NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells","volume":"27","author":"W Qi","year":"2008","journal-title":"Oncogene"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1182\/blood-2010-09-309674","article-title":"Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1","volume":"118","author":"R Balusu","year":"2011","journal-title":"Blood"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0092-8674(00)00093-3","article-title":"Nucleophosmin\/B23 is a target of CDK2\/cyclin E in centrosome duplication","volume":"103","author":"M Okuda","year":"2000","journal-title":"Cell"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1053\/j.seminoncol.2011.04.010","article-title":"Molecular dissection of the 5q deletion in myelodysplastic syndrome","volume":"38","author":"BL Ebert","year":"2011","journal-title":"Semin Oncol"},{"issue":"23","key":"ref36","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"PA Spagnuolo","year":"2010","journal-title":"Blood"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-09-0366","article-title":"Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance","volume":"8","author":"EA Perez","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"ref38","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00018-010-0619-9","article-title":"Teratogenic effects of thalidomide: molecular mechanisms","volume":"68","author":"T Ito","year":"2011","journal-title":"Cell Mol Life Sci"},{"issue":"5971","key":"ref39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"T Ito","year":"2010","journal-title":"Science"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"A Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"18","key":"ref41","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"YX Zhu","year":"2011","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0116135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T20:30:28Z","timestamp":1717705828000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0116135"}},"subtitle":[],"editor":[{"given":"Dominique","family":"Heymann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,1,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0116135","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,24]]}}}